Key Takeaways
(P1) Roivant Sciences Ltd. (Nasdaq: ROIV) reported a fourth-quarter adjusted loss of $0.36 per share, wider than the Zacks Consensus Estimate of a $0.26 loss, as revenue for the period also missed targets.
(P2) "The positive Period 1 data from the IMVT-1402 trial in D2T RA demonstrate exciting potential for a new, differentiated mechanism to treat RA patients who have failed multiple prior therapies,” Matt Gline, CEO of Roivant, said in a statement.
(P3) The company posted revenue of $2.52 million for the quarter ended March 31, a significant drop from the $7.57 million reported in the same period last year. While the company recorded a GAAP net income of $303 million, or $0.28 per share, this was driven by a one-time $770.2 million gain from a litigation settlement. The adjusted non-GAAP loss, which analysts focus on, was $222.7 million for the quarter.
(P4) Despite the earnings miss, the company's stock saw positive movement, largely on the back of promising clinical news. Investors are focused on the potential of Roivant's drug pipeline, which the company bolstered by discontinuing its batoclimab program to concentrate on the more promising IMVT-1402 candidate.
The main driver of investor optimism is the preliminary data from its trial of IMVT-1402 in patients with difficult-to-treat rheumatoid arthritis. In the 16-week initial study period, the drug showed high response rates.
At Week 16, the observed American College of Rheumatology (ACR) response rates were 72.7% for ACR20, 54.5% for ACR50, and 35.8% for ACR70. These metrics represent the percentage of patients achieving a 20%, 50%, and 70% improvement in tender and swollen joint counts, respectively. The results were similarly strong in a subset of patients who had previously failed the most common advanced therapies.
Roivant ended the fiscal year with a strong balance sheet, reporting consolidated cash, cash equivalents, and marketable securities of $4.3 billion as of March 31, 2026. The financial position was strengthened by a $770.2 million gain related to a litigation settlement with Moderna, which is expected to be paid by July 2026.
Research and development expenses increased to $198.9 million for the quarter, up from $145.2 million year-over-year, primarily driven by costs related to the anti-FcRn franchise and the discontinuation of batoclimab.
The results highlight Roivant's strategy of prioritizing high-potential assets within its pipeline. The discontinuation of batoclimab following disappointing Phase 3 results allows the company to focus resources on IMVT-1402, which is now its lead asset. Investors will be closely watching for further updates on the IMVT-1402 program in the second half of 2026.
This article is for informational purposes only and does not constitute investment advice.
